Our top pick for
OptiNose, Inc is a drug manufacturers—specialty & generic business based in the US. OptiNose shares (OPTN) are listed on the NASDAQ and all prices are listed in US Dollars. OptiNose employs 221 staff and has a trailing 12-month revenue of around USD$43.9 million.
|52-week range||USD$3.14 - USD$10.07|
|50-day moving average||USD$3.931|
|200-day moving average||USD$4.7465|
|Wall St. target price||USD$17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.611|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$43.9 million|
|Gross profit TTM||USD$29.3 million|
|Return on assets TTM||-33.93%|
|Return on equity TTM||-279.55%|
|Market capitalisation||USD$227.1 million|
TTM: trailing 12 months
There are currently 6.8 million OptiNose shares held short by investors – that's known as OptiNose's "short interest". This figure is 1.9% up from 6.7 million last month.
There are a few different ways that this level of interest in shorting OptiNose shares can be evaluated.
OptiNose's "short interest ratio" (SIR) is the quantity of OptiNose shares currently shorted divided by the average quantity of OptiNose shares traded daily (recently around 297514.64690497). OptiNose's SIR currently stands at 22.94. In other words for every 100,000 OptiNose shares traded daily on the market, roughly 22940 shares are currently held short.
However OptiNose's short interest can also be evaluated against the total number of OptiNose shares, or, against the total number of tradable OptiNose shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OptiNose's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 OptiNose shares in existence, roughly 130 shares are currently held short) or 0.2285% of the tradable shares (for every 100,000 tradable OptiNose shares, roughly 229 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against OptiNose.
Find out more about how you can short OptiNose stock.
We're not expecting OptiNose to pay a dividend over the next 12 months.
Over the last 12 months, OptiNose's shares have ranged in value from as little as $3.14 up to $10.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OptiNose's is 0.8246. This would suggest that OptiNose's shares are less volatile than average (for this exchange).
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.